Clinical Trials Study
Copyright ©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Sep 28, 2019; 25(36): 5530-5542
Published online Sep 28, 2019. doi: 10.3748/wjg.v25.i36.5530
Genomic profile concordance between pancreatic cyst fluid and neoplastic tissue
Arthur Laquière, Arnaud Lagarde, Bertrand Napoléon, Raphaël Bourdariat, Alexandre Atkinson, Gianfranco Donatelli, Bernard Pol, Laurence Lecomte, Laurence Curel, Romina Urena-Campos, Thierry Helbert, Vincent Valantin, François Mithieux, Jean Pascal Buono, Philippe Grandval, Sylviane Olschwang
Arthur Laquière, Laurence Lecomte, Romina Urena-Campos, Department of Gastroenterology, Saint Joseph Hospital, Marseille 13008, France
Arnaud Lagarde, Alexandre Atkinson, Philippe Grandval, Sylviane Olschwang, Aix-Marseille Univ, INSERM, MMG, Marseille 13385, France
Arnaud Lagarde, AP-HM, Conception Hospital, Marseille 13385, France
Bertrand Napoléon, Raphaël Bourdariat, François Mithieux, RGDS, Jean Mermoz Hospital, Lyon 69008, France
Gianfranco Donatelli, RGDS, Les Peupliers Hospital, Paris 75013, France
Bernard Pol, Department of Digestive Surgery, Saint-Joseph Hospital, Marseille 13008, France
Laurence Curel, Department of Clinical Research, Saint Joseph Hospital, Marseille 13008, France
Thierry Helbert, Vincent Valantin, Sylviane Olschwang, European Hospital, Marseille 13003, France
Jean Pascal Buono, Pathological Anatomy and Cytology, MEDIPATH, Eguilles 13510, France
Philippe Grandval, Sylviane Olschwang, AP-HM, Timone Hospital, Marseille 13005, France
Sylviane Olschwang, RGDS, Clairval Hospital, Marseille 13009, France
Author contributions: Laquière AE and Lagarde A provided equal contributions to the study and the article; All authors met the three conditions of authorship published by the ICMJE: Substantial contribution to conception and design, data acquisition analysis, and interpretation/drafting the article, and making critical revisions/final approval of the final version.
Institutional review board statement: This study has been reviewed by the institutional review board of the Saint Joseph Hospital.
Clinical trial registration statement: This study is registered at The registration identification number is [NCT03305146].
Informed consent statement: All study participants or their legal guardian provided informed written consent about personal and medical data collection prior to study enrolment. All involved persons (subjects or legally authorized representative) gave their written informed consent prior to study inclusion.
Conflict-of-interest statement: The authors do not have any conflicts of interest to disclose.
CONSORT 2010 statement: The authors have read the CONSORT 2010 Statement, and the manuscript was prepared and revised according to the CONSORT 2010 Statement.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Corresponding author: Arthur Laquière, MD, Hepatogastroenterologist, Department of Gastroenterology, Saint Joseph Hospital, 26 bd de Louvain, Marseille 13008, France.
Telephone: +33-4-91801822 Fax: +33-4-91806912
Received: April 30, 2019
Peer-review started: April 30, 2019
First decision: May 30, 2019
Revised: July 16, 2019
Accepted: August 19, 2019
Article in press: Auguet 19, 2019
Published online: September 28, 2019
Core Tip

Core tip: This pilot study (20 patients) was a comparative next-generation sequencing mutational analysis between pancreatic cyst fluid (CF) and neoplastic surgical tissue (NT) to confirm whether the CF genomic profile was a reliable malignancy predictor. Concordant genotypes were found in 15 of 17 paired DNA samples. The sensitivity and specificity of CF mutations to predict an appropriate indication for surgical resection were 0.78 and 0.62 for the KRAS/GNAS mutations and 0.55 and 1.0 for the RAF/PTPRD/CTNNB1/RNF43/POLD1/TP53 mutations, respectively. Mutational analyses of CF and NT were highly concordant, confirming the interest of CF next-generation sequencing analysis in the preoperative malignancy assessment.